Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.11 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: lecanemab, tramiprosate, donanemab +10 | 0.90 |
| trials ClinicalTrials.gov | 246 Parkinson's trials, 3 stopped | 0.95 |
| literature PubMed | 718 Parkinson's papers of 57,729: well-trodden | 0.14 |
| pathways Reactome | 20 pathways; mostly lysosome and autophagy | 1.00 |
No case: the score is under the bar. Receipt 2493
Sealed predictions
- APP in dopamine neurons, braak+0.29 (p 0.443) → +0.56 (p 0.116)receipt 2500
Swarm cases
receipt 2500: APP in dopamine neurons, braak
- power
- full sample +0.48 (p 0.042, n 18), 95% CI +0.02 to +0.78. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.50 (p 0.033, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.59 (p 0.0092, n 18). not the mix.
- skeptic
- leave-one-out range +0.41 to +0.57, sign flips 0; without severely affected donors +0.48 (p 0.042, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for APP in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts